One hundred ten patients with advanced ovarian carcinoma (Stages IIIA, IIIB, and 1V) were evaluated for survival. They received as first treatment one of the following regimens: melphalan (L-PAM) (41 patients), cyclophosphamide plus methotrexate plus 5-fluorouracil (CMF) (16 patients), cyclophospham
Genetic factors in ovarian carcinoma
โ Scribed by Andrew J. Li; Beth Y. Karlan
- Book ID
- 107546061
- Publisher
- Current Science Inc.
- Year
- 2001
- Tongue
- English
- Weight
- 262 KB
- Volume
- 3
- Category
- Article
- ISSN
- 1523-3790
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
1 year end results of 200 patients with ovarian carcinoma seen at the Sloane Hospital for Women (Presbyterian) between 1922 and 1944. The relative 5-year-survival rate for these patients was 30.8 per cent and the absolute rate, 27.5 per cent. T h e histories, operative findings, and pathological mat
## Abstract ## BACKGROUND: Research suggests that glucose levels in cancer patients may be an important prognostic indicator. In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time in ova
Communicated by David W. Yandell Genome scanning, originally used to detect mouse mutations, is a technique which can rapidly identify differences between genomic D N A samples. The procedure is essentially a high resolution Southern analysis using a probe that hybridizes to a medium copy number (10
To identify factors that might be useful as prognostic indexes for the risk of hepatocellular carcinoma in Italian patients with genetic hemochromatosis, 152 homozygotes were studied prospectively for 1 to 229 mo. Factors that were considered in estimating the risk of developing hepatocellular carci